#USA #San Diego #Baylor College #Alida Biosciences #GARP Core

AlidaBio Launches RNA Modification Sequencing Partnership

Alida Biosciences, a leading innovator in RNA modification analysis, has announced a significant collaboration with Baylor College of Medicine. This partnership is centered around the GARP Core, a renowned genomic service provider, which will leverage AlidaBio's state-of-the-art EpiPlex™ Platform for multiplexed RNA modification sequencing.

Advancements in RNA Analysis

Launched in February 2025, the EpiPlex Platform is groundbreaking in its ability to detect and quantify multiple RNA modifications while simultaneously analyzing gene expression. This technology represents a pioneering step in RNA biology, offering researchers enhanced insights into how RNA modifications impact development, aging, and disease.

Dr. Gudrun Stengel, CEO of AlidaBio, expressed her enthusiasm, stating, "We're thrilled to witness our first official service provider emerge from an esteemed institution like Baylor College of Medicine. The collaboration combines GARP's extensive knowledge in transcriptomic profiling with our advanced RNA modification technology, enabling researchers access to innovative capabilities through a trusted partner."

Unmatched Capabilities

The EpiPlex RNA Library Prep Kit is designed for clinical and translational research, optimizing for samples that contain limited RNA amounts. With sensitivity as low as 50 ng of total RNA, the platform can yield high-resolution data even from challenging samples, such as tissue biopsies or FFPE samples, where RNA tends to be lower quality and fragmented.

In tandem, the EpiScout™ Analysis Suite provides users with an intuitive informatics platform that automates the analysis and visualization of intricate epitranscriptomic data. By integrating expression data with various RNA modifications, it offers researchers a holistic view of transcriptome regulation without the usual challenges associated with bioinformatics.

The EpiPlex assay has been designed not only for accuracy and reproducibility but also for efficiency; the wet-lab portion of the workflow can be completed within a single day. This feature makes it accessible for laboratories of all sizes, available in both 8- and 24-sample formats.

Future Expansion

As AlidaBio continues to innovate, plans are underway to expand the EpiPlex platform further. This will include the addition of more modification targets, enhanced base resolution, and targeted panels specifically created for drug discovery and applications in disease research.

Dr. Daniel Kraushaar, Director of the GARP Core, emphasized the significance of the technology, stating, "This platform represents a transformative leap in RNA analysis. Researchers are now equipped to assess both gene expression and multiple RNA modifications concurrently, paving the way for groundbreaking insights into post-transcriptional regulation. We are excited to extend this cutting-edge technology to the Baylor research community and beyond."

Conclusion

Alida Biosciences' partnership with Baylor College of Medicine signifies a pivotal advancement in RNA modification research. By harnessing innovative tools and fostering collaborations, they are poised to drive discoveries that can revolutionize our understanding of RNA biology. For more details about AlidaBio's offerings, visit www.alidabio.com.